AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.



Biotechnology

AC Immune

Andrea Pfeifer

Christopher R.

Madiha Derouazi

Nuno Mendonça

Bojana Portmann

Julien Rongère

Marie Kosco-Vilbois

Piergiorgio Donati

Christopher Roberts

Jean-Fabien Monin

Howard Donovan

Scientific & Research Team

Leadership Team

Finance Team

Clinical Operations Team

Teams at AC Immune

Scientific & Research Team

Leadership Team

Finance Team

Clinical Operations Team